Retatrutide
Phase 3Peptide
Eli LillyRetatrutide is a peptide that works as a Gip/glp-1/glucagon Triple Agonist.[2] It is being investigated across 13 indications, with its most advanced program in Phase 3.[1]
Retatrutide is one of 342 peptide programs targeting Hepatic failure. It is currently in Phase 3.
13
Indications
19
Total Trials
15
Active Trials
341
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Retatrutide
Eli LillyPhase 3
Byetta
AstraZenecaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes4 trials
Show 1 more trial
Obesity3 trials
Type 2 Diabetes Mellitus3 trials
Overweight3 trials
5 more indications
Chronic Kidney Disease1 trial
Osteoarthritis1 trial
Low back pain1 trial
Tics1 trial
Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Retatrutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]